Jiangsu Bioperfectus Technologies Co., Ltd. (abbreviated as "Bioperfectus", with stock code "688399") was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on December 5, 2019, with an issue price of 46.78 yuan.

Bioperfectus' revenue in the first nine months of 2019 was 190 million yuan, an increase of 20.25% over the same period last year; net profit was 49.77 million yuan, an increase of 26.53% over the same period last year.

From 2010 to 2019, for ten years, upholding the original intention of solving practical clinical problems and innovating disease diagnosis technology, Bioperfectus people have worked hard and arduously, finally making Bioperfectus one of the leading in vitro diagnostic companies in China.

In the future, we Bioperfectus will continue to bear our original intention in mind, work hard and move forward bravely!